Two of the biggest trials reached opposite conclusions, and the disagreement is still unresolved. For most healthy people who eat fish, a pill is optional.
The one-paragraph version
The strongest, least controversial use of omega-3s (EPA and DHA) is lowering high triglycerides, where high doses reliably work S1S4. As general heart protection for healthy people, the evidence is a mess: the REDUCE-IT trial found a 25% reduction in cardiovascular events with 4 g/day of purified EPA, but the STRENGTH trial, using an EPA+DHA combination, found nothing and stopped early S2S3. Part of the gap may be REDUCE-IT's mineral-oil placebo, which may have made the drug look better by comparison S2. If you don't eat oily fish, a modest daily dose is a reasonable insurance policy; if you eat fish regularly, you probably don't need it.
What it is and how it works
Omega-3s are essential fats. The two that matter most are marine EPA and DHA, found in oily fish; the plant form ALA (flax, walnuts) converts to EPA/DHA only inefficiently S1. They lower triglycerides, have anti-inflammatory effects, and are structural components of cell membranes and the brain and retina S1.
What the evidence actually supports
Lowering high triglycerides — strong. High-dose omega-3s (typically ~4 g/day) reliably reduce elevated triglycerides, which is why prescription formulations exist and why the AHA endorses them for hypertriglyceridemia S1S4. This is the clearest win.
General cardiovascular prevention — contradictory. This is the honest heart of the matter. REDUCE-IT (4 g/day icosapent ethyl, purified EPA, on top of statins) cut major adverse cardiovascular events by ~25% S2. STRENGTH (a high-dose EPA+DHA carboxylic acid) was halted early for futility — no cardiovascular benefit S2S3. Both lowered triglycerides similarly, so triglyceride-lowering alone doesn't explain the split S2. Leading explanations: the two formulations differ (EPA-only vs. EPA+DHA), and REDUCE-IT's mineral-oil placebo may have raised LDL/inflammation markers in the control arm, exaggerating the apparent benefit S2. The field has not settled this.
Everyday fish-oil pills for healthy people — modest at best. Large trials and meta-analyses of standard over-the-counter doses show small or inconsistent cardiovascular effects in general populations S1. Eating fish beats supplementing for most people.
Who actually benefits
People with high triglycerides (under medical care), and people who rarely or never eat oily fish and want to cover the EPA/DHA gap S1. Regular fish eaters get diminishing returns from a pill.
Dosing (standard, well-established)
For general intake, guidance favors eating oily fish twice a week; supplement doses commonly provide ~250–1000 mg/day of combined EPA+DHA for people who don't S1. Check the label for EPA+DHA content, not total fish-oil weight — a "1000 mg fish oil" softgel often contains only ~300 mg EPA+DHA. The ~4 g/day used for triglycerides is a prescription-level, clinician-supervised dose, not a casual OTC choice S1S4.
Safety
Generally well tolerated. Common complaints are fishy aftertaste, burping, and GI upset S1. At high doses omega-3s modestly increase bleeding tendency and raise atrial-fibrillation risk in some trials, so people on anticoagulants or with arrhythmia history should involve a clinician S1. Quality caveat: fish oil is prone to oxidation (rancidity); an off or strongly fishy smell can indicate a degraded product, and third-party testing for freshness, potency, and contaminants (mercury, PCBs) is worth prioritizing over brand claims.
The marketing myths
- "Fish oil protects everyone's heart." Overstated — the two biggest trials disagree, and general-population benefit is weak S2S3.
- "1000 mg fish oil = 1000 mg omega-3." No — read the EPA+DHA line S1.
- "More is always better / OTC equals the trial doses." The cardioprotective/triglyceride doses are prescription-level and supervised S1S4.
- "All fish oil is the same." Oxidation and contaminant load vary; freshness and third-party testing matter more than the label story.
Sources
Every reference below is a primary source cited in this guide.